keyword
https://read.qxmd.com/read/38672276/atorvastatin-treatment-significantly-increased-the-concentration-of-bone-marrow-derived-mononuclear-cells-and-transcutaneous-oxygen-pressure-and-lowered-the-pain-scale-after-bone-marrow-cells-treatment-in-patients-with-no-option-critical-limb-ischaemia
#61
JOURNAL ARTICLE
Jan Kyselovic, Adriana Adamičková, Andrea Gažová, Simona Valášková, Nikola Chomaničová, Zdenko Červenák, Juraj Madaric
BACKGROUND: The present study investigated the outcomes and possible predictive factors of autologous bone marrow cells (BMCs) therapy in patients with "no-option" critical limb ischaemia (CLI). It was focused on exploring the clinical background and prior statin and renin-angiotensin system (RAS)-acting agents pharmacotherapy related to the therapeutic efficacy of BMCs treatment. METHODS: In the present study, we reviewed thirty-three patients (mean age 64.9 ± 10 years; 31 males) with advanced CLI after failed or impossible revascularisation, who were treated with 40 mL of autologous BMCs by local intramuscular application...
April 22, 2024: Biomedicines
https://read.qxmd.com/read/38669142/environmental-purines-decrease-pseudomonas-aeruginosa-biofilm-formation-by-disrupting-c-di-gmp-metabolism
#62
JOURNAL ARTICLE
Corey Kennelly, Peter Tran, Arthur Prindle
Cyclic di-guanosine monophosphate (c-di-GMP) is a bacterial second messenger that governs the lifestyle switch between planktonic and biofilm states. While substantial investigation has focused on the proteins that produce and degrade c-di-GMP, less attention has been paid to the potential for metabolic control of c-di-GMP signaling. Here, we show that micromolar levels of specific environmental purines unexpectedly decrease c-di-GMP and biofilm formation in Pseudomonas aeruginosa. Using a fluorescent genetic reporter, we show that adenosine and inosine decrease c-di-GMP even when competing purines are present...
April 25, 2024: Cell Reports
https://read.qxmd.com/read/38666789/impact-of-blood-salvage-therapy-during-oncologic-liver-surgeries-on-allogenic-transfusion-events-survival-and-recurrence-an-ambidirectional-cohort-study
#63
JOURNAL ARTICLE
Liav Lugassy, Samuel Marion, Frédéric Balthazar, Sonia Gabriela Cheng Oviedo, Yves Collin
INTRODUCTION: The use of autologous blood transfusions in oncologic surgeries is somewhat controversial due to the potential risk of disease dissemination through the salvage process. On the other hand, autologous blood transfusion can prevent the potential negative effects of allogenic blood transfusions and reduce use of valuable resources. METHODS: This study included 106 adult patients who underwent oncologic liver surgery at our institution between December 2015 and June 2019...
April 26, 2024: International Journal of Surgery
https://read.qxmd.com/read/38662205/daratumumab-and-venetoclax-combined-with-cage-for-late-r-r-t-all-lbl-patients-single-arm-open-label-phase-i-study
#64
JOURNAL ARTICLE
Hui Shi, Fan Yang, Miaomiao Cao, Teng Xu, Peihao Zheng, Yuelu Guo, Guoai Su, Shaomei Feng, Ruiting Li, Rui Liu, Haidi Liu, Lixia Ma, Xiaoyan Ke, Kai Hu
The prognosis of patients diagnosed with relapsed or refractory (R/R) T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) has consistently been unsatisfactory, with limited treatment options. As reports, the CAG regimen can serve as a salvage treatment for R/R T-ALL/LBL, but there remains a subset of patients who do not benefit from it. Recent studies have indicated that daratumumab (Dara) and venetoclax (Ven) may offer promising therapeutic benefits for T-ALL/LBL. In light of these findings, we conducted a safety and efficacy evaluation of the enhanced treatment regimen, combining Dara and Ven with aclarubicin, cytarabine, granulocyte colony-stimulating factor, and etoposide (CAGE), in patients suffering from R/R T-ALL/LBL...
April 25, 2024: Annals of Hematology
https://read.qxmd.com/read/38660343/achieving-complete-metabolic-response-in-stage-iv-lung-adenocarcinoma-with-chemotherapy-nivolumab-ipilimumab-and-salvage-sbrt-a-case-report
#65
Salvador Gamez Casado, Javier David Benitez Fuentes, Beatriz Álvarez Rodríguez, Gema García Ledo
Oncogene-negative, PDL1-negative metastatic non-small cell lung cancer (NSCLC) presents significant treatment challenges due to its complexity and resistance to conventional therapies. The case report presented addresses a 55-year-old male patient with oncogene-negative, PDL1-negative stage IV lung adenocarcinoma, showcasing an exceptional complete metabolic response to a multimodality treatment combining double immune checkpoint inhibition (ICI) and chemotherapy, followed by salvage stereotactic body radiotherapy (SBRT)...
April 2024: Respirology Case Reports
https://read.qxmd.com/read/38659569/a-deeper-depth-of-response-after-salvage-therapy-improves-outcomes-of-autologous-stem-cell-transplantation-in-relapsed-lymphoma-and-the-feasibility-of-non-controlled-rate-freezing-of-peripheral-blood-stem-cells
#66
JOURNAL ARTICLE
Saif Ur Rab, Mussadique Ali, Uzma Rasool Mahar, Bushra Ahsan, Usman Ahmad, Muhammad Tariq Mahmood, Neelam Siddiqui, Syed W Bokhari
Background High-dose chemotherapy followed by autologous stem cell transplantation is considered a standard treatment approach for patients with relapsed Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL). The goal of autologous stem cell transplant in relapsed lymphoma is to achieve long-term disease control, i.e., cure, in contrast to disorders like multiple myeloma, where it only prolongs the duration of remission, progression-free survival, and improves the quality of life. Published outcomes of high-dose therapy and ASCT and the impact of different factors affecting survival in low- to middle-income countries are very limited...
March 2024: Curēus
https://read.qxmd.com/read/38658605/risk-factors-and-predictive-nomograms-for-bedside-emergency-endoscopic-treatment-following-endotracheal-intubation-in-cirrhotic-patients-with-esophagogastric-variceal-bleeding
#67
JOURNAL ARTICLE
Ajuan Zeng, Yangjie Li, Lingna Lyu, Shibin Zhang, Yuening Zhang, Huiguo Ding, Lei Li
Data on emergency endoscopic treatment following endotracheal intubation in patients with esophagogastric variceal bleeding (EGVB) remain limited. This retrospective study aimed to explore the efficacy and risk factors of bedside emergency endoscopic treatment following endotracheal intubation in severe EGVB patients admitted in Intensive Care Unit. A total of 165 EGVB patients were enrolled and allocated to training and validation sets in a randomly stratified manner. Univariate and multivariate logistic regression analyses were used to identify independent risk factors to construct nomograms for predicting the prognosis related to endoscopic hemostasis failure rate and 6-week mortality...
April 24, 2024: Scientific Reports
https://read.qxmd.com/read/38658209/high-dose-chemotherapy-with-autologous-stem-cell-transplant-for-patients-with-advanced-germ-cell-tumors-real-world-evidence-from-a-tertiary-cancer-center-in-brazil
#68
JOURNAL ARTICLE
Gabriel Berlingieri Polho, Mateus Trinconi Cunha, Maiana Hamdan Melo Coelho, Jamile Almeida-Silva, Cassio Murilo Hidalgo Filho, Erick Menezes Xavier, Nathalia de Souza Crusoe, Marcelo Junqueira Atanazio, Vitor Fiorin de Vasconcellos, Vivian Naomi Horita, Guilherme Fialho Freitas, David Queiroz Muniz, Vanderson Rocha, Jose Mauricio Mota
BACKGROUND: High-dose chemotherapy followed by stem cell transplant (HDCT) is potentially curative for patients with refractory germ cell tumors (rGCT). There is scarce real-world data supporting its implementation in low- and middle-income countries. We described the experience of our tertiary cancer center in Sao Paulo, Brazil. METHODS: We identified male patients ≥18 years-old with rGCT referred to HDCT after board discussion. Clinical data, including delays in HDCT protocol, were extracted from medical records, and survival outcomes were estimated using the Kaplan-Meier method...
March 24, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38651430/surgical-outcomes-and-complications-of-custom-made-prostheses-in-upper-limb-oncological-reconstruction-a-systematic-review
#69
REVIEW
Camillo Fulchignoni, Silvia Pietramala, Ivo Lopez, Giovan Giuseppe Mazzella, Chiara Comisi, Carlo Perisano, Lorenzo Rocchi, Tommaso Greco
Bone tumors of the upper limb are a common cause of bone pain and pathological fractures in both old and young populations. Surgical reconstruction and limb salvage have become valid options for these patients despite this kind of surgery being challenging due to the need for wide bone resection and the involvement of surrounding soft tissues. Computer-assisted technology helps the surgeon in pre-operative planning and in designing customized implants. The aim of this study was to investigate the surgical outcomes and complications of custom-made prostheses in oncologic reconstruction of the upper limb and if they are reliable options for patients suffering from aggressive tumors...
April 11, 2024: Journal of Functional Morphology and Kinesiology
https://read.qxmd.com/read/38646700/network-meta-analysis-of-car-t-cell-therapy-for-the-treatment-of-3l-r-r-lbcl-after-using-published-comparative-studies
#70
REVIEW
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R Patel, Frederick L Locke
INTRODUCTION: Studies have compared chimeric antigen receptor (CAR) T-cell therapies and salvage chemotherapy in relapsed/refractory large B-cell lymphoma (LBCL) patients, but further evidence of their relative effectiveness is warranted. METHODS: Our systematic review identified studies comparing efficacy and safety outcomes of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) trials to salvage chemotherapy cohorts in LBCL patients with ≥ 2 prior lines of treatment; and an extended evidence network included indirect comparisons comparing CAR T-cell therapies...
April 22, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38644986/clinical-efficacy-of-programmed-cell-death-ligand-1-antibody-in-treatment-of-extranodal-natural-killer-t-cell-lymphoma-with-hemophagocytic-lymphohistiocytosis
#71
Chun Li Yang, Xi Chen, Hui Jie Zhou, Wan Chun Wu, Li Qun Zou
Extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis (ENKTCL-LAHS) is a rare disease with poor prognosis. Currently, there are no well-established treatments for LAHS. Almost 50% of patients experience relapsed or refractory disease to anti-hemophagocytic lymphohistiocytosis (HLH) treatment, and the regimen for salvage therapy is limited. We report a case of ENKTCL-LAHS that was successfully treated with a programmed cell death ligand 1 (PD-L1) antibody (sugemalimab) alone and provide a literature review on existing ENKTCL-LAHS treatment options...
April 2024: Journal of Hematology (Brossard, Quebec)
https://read.qxmd.com/read/38644499/graft-failure-after-allogeneic-hematopoietic-stem-cell-transplantation-in-pediatric-patients-with-acute-leukemia-autologous-reconstitution-or-second-transplant
#72
REVIEW
Tahereh Rostami, Mohammad Reza Rostami, Amir Hossein Mirhosseini, Saeed Mohammadi, Mohsen Nikbakht, Hediyeh Alemi, Naghmeh Khavandgar, Soroush Rad, Ghasem Janbabai, Seied Asadollah Mousavi, Azadeh Kiumarsi, Amir Kasaeian
BACKGROUND: Graft failure (GF) is a rare but serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of graft failure remains the most advisable approach as there is no clear recommendation for the best strategies for reversing this complication. Administration of growth factor, additional hematopoietic progenitor boost, or a salvage HSCT are current modalities recommended for the treatment of GF. Autologous recovery without evidence of disease relapse occurs rarely in patients with GF, and in the absence of autologous recovery, further salvage transplantation following a second conditioning regimen is a potential treatment option that offers the best chances of long-term disease-free survival...
April 22, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38637253/impact-of-cell-salvage-on-hematocrit-and-post-partum-anemia-in-low-hemorrhage-risk-elective-cesarean-delivery
#73
JOURNAL ARTICLE
Daniel Katz, Annalin Griffel, Sarah Granozio, Gary Koenig, Hung-Mo Lin
BACKGROUND: Postpartum anemia is a significant contributor to peripartum morbidity. The utilization of cell salvage in low risk cases and its impact on postpartum anemia has not been investigated. We therefore aimed to examine the impact of autologous blood transfusion/cell salvage in routine cesarean delivery on postoperative hematocrit and anemia. STUDY DESIGN AND METHODS: Retrospective cohort study from a perfusion database from a large academic center where cell salvage is performed at the discretion of the obstetrical team...
April 16, 2024: Transfusion and Apheresis Science
https://read.qxmd.com/read/38636710/re-irradiation-versus-systemic-therapy-for-the-management-of-local-regionally-recurrent-head-and-neck-cancer
#74
JOURNAL ARTICLE
Allen M Chen, Jeremy P Harris, Rupali Nabar, Tjoson Tjoa, Yarah Haidar, William B Armstrong
PURPOSE: The optimal management of local-regionally recurrent head and neck cancer that is not amenable to surgical resection is uncertain. We sought to compare outcomes among patients treated with and without re-irradiation in this setting. METHODS AND MATERIALS: A review of institutional registries identified 65 patients with local-regionally recurrent squamous cell carcinoma of the head and neck who were ineligible for surgery. Forty patients (62 %) opted for re-irradiation with the remaining 25 patients (38 %) undergoing initial systemic therapy alone...
April 16, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38631712/combinational-therapy-of-car-t-cell-and-hdt-asct-demonstrates-impressive-clinical-efficacy-and-improved-car-t-cell-behavior-in-relapsed-refractory-large-b-cell-lymphoma
#75
JOURNAL ARTICLE
Wei Liu, Wei Liu, Hesong Zou, Lianting Chen, Wenyang Huang, Rui Lv, Yan Xu, Huimin Liu, Yin Shi, Kefei Wang, Yi Wang, Wenjie Xiong, Shuhui Deng, Shuhua Yi, Weiwei Sui, Guangxin Peng, Yueshen Ma, Huijun Wang, Lulu Lv, Jianxiang Wang, Jun Wei, Lugui Qiu, Wenting Zheng, Dehui Zou
BACKGROUND: Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have suggested that intensified lymphodepletion and hematological stem cell infusion can promote adoptively transferred T-cell expansion, enhancing antitumor effects. Therefore, we conducted a phase I/II clinical trial in which CNCT19 (an anti-CD19 CAR T-cell) was administered after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) in patients with R/R LBCL...
April 16, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38631319/challenges-and-pitfalls-in-pancreatobiliary-cytopathology
#76
Jose Victor Scarpa-Carniello, Momin T Siddiqui
BACKGROUND: The advances of minimally invasive endoscopy-guided procedures that usually yield limited diagnostic material changed pancreaticobiliary cytopathology into one of the most challenging areas of Cytopathology given the abundance of differential diagnoses to be considered when dealing with limited specimens. SUMMARY: We describes a few challenging, examples of potential pitfalls in pancreatobiliary cytopathology evaluation collected from a busy academic hospital (tertiary) center...
April 17, 2024: Acta Cytologica
https://read.qxmd.com/read/38629176/flotetuzumab-as-a-salvage-immunotherapy-in-advanced-cd123-positive-hematological-malignancies-a-phase-1-pilot-study
#77
JOURNAL ARTICLE
Ibrahim Aldoss, Jianying Zhang, Marjorie Robbins, Joo Song, Monzr M Al Malki, Salman Otoukesh, Karamjeet Sandhu, Vaibhav Agrawal, Alex F Herrera, Leslie L Popplewell, Lucy Ghoda, Anthony Stein, Guido Marcucci, Stephen Forman, Vinod Pullarkat
CD123 "expression" is common in hematological malignancies, including acute lymphoblastic leukemia (ALL). Flotetuzumab is a novel, investigational CD3/CD123 DART®. We conducted a phase 1 study evaluating safety and efficacy of flotetuzumab in relapsed/refractory ALL (Cohort A) and other advanced CD123-positive hematological malignancies (excluding myeloid malignancies) (cohort B). Thirteen patients (9 in Cohort A and 4 in Cohort B) were treated at dose level 1 (500 ng/kg/day) before early closure due to discontinuation of drug development by sponsor...
April 17, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38626697/post-treatment-magnetic-resonance-imaging-predicts-outcomes-of-maxillary-sinus-cancer-treatment-using-super-selective-intra-arterial-infusion-of-high-dose-cisplatin-with-concomitant-radiotherapy-radplat
#78
JOURNAL ARTICLE
Hideomi Yamauchi, Akira Baba, Nobuhiro Ogino, Satoshi Matsushima, Hirokazu Ashida, Masato Nagaoka, Hiroya Ojiri
OBJECTIVES: This study aimed to evaluate the prognostic value of magnetic resonance imaging (MRI) findings in predicting local recurrence in patients with maxillary sinus cancer treated with super-selective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy (RADPLAT). METHODS: This single-center retrospective study included consecutive patients with maxillary sinus squamous cell carcinoma, who underwent RADPLAT between October 2016 and September 2021...
April 15, 2024: Auris, Nasus, Larynx
https://read.qxmd.com/read/38624243/lipoic-acid-attachment-to-proteins-stimulating-new-developments
#79
REVIEW
John E Cronan
SUMMARYLipoic acid-modified proteins are essential for central metabolism and pathogenesis. In recent years, the Escherichia coli and Bacillus subtilis lipoyl assembly pathways have been modified and extended to archaea and diverse eukaryotes including humans. These extensions include a new pathway to insert the key sulfur atoms of lipoate, several new pathways of lipoate salvage, and a novel use of lipoic acid in sulfur-oxidizing bacteria. Other advances are the modification of E. coli LplA for studies of protein localization and protein-protein interactions in cell biology and in enzymatic removal of lipoate from lipoyl proteins...
April 16, 2024: Microbiology and Molecular Biology Reviews: MMBR
https://read.qxmd.com/read/38623016/-l-dep-regimen-salvage-therapy-for-refractory-primary-hemophagocytic-lymphohistiocytosis-triggered-by-epstein-barr-virus-infection-in-4-children
#80
JOURNAL ARTICLE
Y Z Zhao, H H Ma, H Y Lian, D Wang, T Y Wang, R Zhang
Objective: To analyze the efficacy and safety of the L-DEP regimen (asparaginase, liposome doxorubicin, etoposide and methylprednisolone) as a salvage therapy for the refractory primary hemophagocytic lymphohistocytosis triggered by Epstein-Barr virus infection (EBV-pHLH) in children. Methods: In this retrospective case study, clinical and laboratory data before and after L-DEP regimen of 4 children diagnosed with EBV-pHLH in Beijing Children's hospital between January 2016 and June 2022 were collected, and the efficacy and safety of L-DEP regimen for the treatment of EBV-pHLH were analyzed...
April 16, 2024: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
keyword
keyword
95772
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.